Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02502708
Other study ID # NLG2105
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2015
Est. completion date February 28, 2020

Study information

Verified date June 2020
Source Lumos Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors. Using a preclinical glioblastoma model, it was recently shown that adding IDO-blocking drugs to temozolomide plus radiation significantly enhanced survival by driving a vigorous, tumordirected inflammatory response. This data provided the rationale for the companion adult phase 1 trial using indoximod (IND#120813) plus temozolomide to treat adults with glioblastoma, which is currently open (NCT02052648). The goal of this pediatric study is to bring IDO-based immunotherapy into the clinic for children with brain tumors. This study will provide a foundation for future pediatric trials testing indoximod combined with radiation and temozolomide in the up-front setting for patients with newly diagnosed central nervous system tumors.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date February 28, 2020
Est. primary completion date December 12, 2019
Accepts healthy volunteers No
Gender All
Age group 3 Years to 21 Years
Eligibility Eligibility Criteria

- Age: 3-21 years.

- Group 1 or Group 3: histologically proven initial diagnosis of primary malignant brain tumor, with no known curative treatment options.

- Group 2: histologically proven initial diagnosis of high-grade glioma (WHO grade III and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor.

- Group 3b: Patients with a radiographic diagnosis or histologically proven diagnosis of diffuse intrinsic pontine glioma (DIPG).

- MRI confirmation of tumor progression or regrowth.

- Patients must be able to swallow whole capsules.

- Patients with metastatic disease are eligible for enrollment.

- Lansky or Karnofsky performance status score must be > 50%.

- Seizure disorders must be well controlled on antiepileptic medication.

- DIPG patients enrolled to Group 3b must not have been previously treated with radiation or any medical therapy.

- Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment.

Exclusion Criteria

- Prior invasive malignancy, other than the primary central nervous system tumor, unless the patient has been disease free and off therapy for that disease for a minimum of 3 years

- Patients with baseline QTc interval of more than 470 msec at study entry, and patients with congenital long QTc syndrome.

- Active autoimmune disease

Study Design


Intervention

Drug:
Indoximod
Indoximod will be administered orally twice daily.
Temozolomide
Temozolomide will be administered on days 1-5 of every 28 day cycle.
Radiation:
Conformal Radiation
Conformal radiation will be administered on days 3-7 of induction cycle.
Drug:
Cyclophosphamide
Cyclophosphamide will be administered orally daily.
Etoposide
Etoposide will be administered orally daily.

Locations

Country Name City State
United States Children's Heathcare of Atlanta Atlanta Georgia
United States Augusta University Augusta Georgia
United States Children's Hospital Colorado Aurora Colorado
United States Children's Hospitals and Clinics of Minnesota Minneapolis Minnesota
United States Arnold Palmer Hospital for Children Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
NewLink Genetics Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of regimen limiting toxicities (RLTs) To estimate the RP2D of indoximod combined with temozolomide First 28 days of treatment
Primary Objective Response Rate To assess preliminary evidence of efficacy of indoximod and temozolomide using COG brain tumor measurement criteria. Up to three years
Primary Incidence of regimen limiting toxicities (RLTs) To estimate the RP2D of indoximod combined with conformal radiation First 35 days of treatment
Primary Safety and tolerability assessed by development of AEs and laboratory parameters of indoximod in combination with cyclophosphamide and etoposide. In patients who initially achieve prolonged stable disease or better with Indoximod plus temozolomide but then develop progressive disease Up to three years
Secondary Pharmacokinetics: Serum concentrations (Cmax/Steady State) Group 1 First 48 hours of treatment
Secondary Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions. Group 1 and 2 Continuous during study until 30 days after study treatment is complete.
Secondary Progression Free Survival (PFS) Group 2 Up to three years
Secondary Time to Progression Group 2 Start of study until disease progression follow-up, up to three years
Secondary Overall Survival Group 2 Start of study until end of follow-up, up to five years
Secondary Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions. Group 3 Continuous during study until 30 days after study treatment is complete.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04539574 - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors N/A
Enrolling by invitation NCT04461002 - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT03242824 - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Phase 2
Recruiting NCT04186832 - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy N/A
Completed NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) Phase 2
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Phase 2
Terminated NCT04556929 - Enhanced Detection in Glioma Excision N/A
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Recruiting NCT06043232 - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting NCT06043765 - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training N/A
Not yet recruiting NCT05025969 - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Completed NCT01479686 - iMRI Guided Resection in Cerebral Glioma Surgery Phase 3
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2

External Links